Two-Dose Heartworm Treatment Achieves 95.3% Efficacy in Clinical Trial

A shorter course for a difficult shelter problem

For shelters balancing heartworm care with limited staff, space and budgets, shortening treatment could make a practical difference. A randomized trial reports that a two-dose melarsomine protocol achieved 95.3% efficacy, close to the 98.8% recorded with the standard three-dose course. That gap matters: the shorter schedule did not match the standard protocol’s reported result, but the trial suggests it may offer a workable option in the setting it studied.

Heartworm treatment is a sequence of care, not simply a pair of injections. Shelters must coordinate medication, monitoring, restricted activity and the dog’s day-to-day needs while working with finite kennel space and staff time. A protocol that removes a visit may ease some of that coordination. It won’t eliminate the work involved, though, and the reported efficacy figures don’t tell shelters how much time or money they’d save in practice.

Published in the Journal of the American Veterinary Medical Association (JAVMA), the study followed 168 dogs with Class 1 or 2 heartworm disease. The trial ran from April 2024 through December 2025 and assessed both protocols alongside doxycycline, moxidectin and prednisone. Its scope is therefore specific: the results describe dogs in those disease classes receiving the studied treatment combinations.

That qualification is useful for readers weighing the finding. A result from one defined group can inform shelter decisions, but it doesn’t establish that the same schedule is appropriate for every heartworm-positive dog. The article reports a randomized comparison, which gives the efficacy figures a direct basis for comparison within the study. It doesn’t provide enough detail here to judge how the result might vary across other patient groups or shelter settings.

Two injections instead of three

Dogs in the compressed group received melarsomine on consecutive days 14 and 15. The standard group was treated on days 14, 44 and 45. Both groups were restricted from exercise for four weeks after treatment. So the shorter protocol changes the timing and number of melarsomine doses; it doesn’t remove the shared exercise restriction or the other medications used in the trial.

That distinction matters operationally. Fewer scheduled injections may reduce some demands on staff and simplify parts of a care plan, while exercise restriction still requires shelters to manage dogs’ activity over time. In practice, a shorter medication schedule is only one piece of the workload. The researchers’ findings make the approach worth attention, but the reported results don’t quantify the practical savings or show how shelters should adapt their staffing and housing plans.

All dogs survived, and complications were uncommon. Seven needed chest radiographs, with some receiving additional treatment; none required intensive management. Those outcomes are reassuring within the group studied, though “uncommon” shouldn’t be read as “absent.” The imaging and additional care also show that a streamlined protocol still calls for clinical observation and a plan for dogs who need follow-up.

This is more significant than it looks for shelters managing treatment capacity: reducing one dose could make a case easier to schedule, especially when a facility is trying to care for multiple animals with limited resources. But efficacy remains part of the trade-off. The two-dose result was close to, rather than equal to, the standard course’s reported figure. Any decision about using it needs to account for that difference and the limits of the study population.

Study partners and findings

The research involved Lucky Dog Animal Rescue, the University of Florida Shelter Medicine Program, Toronto Humane Society and PetSmart Charities. The authors concluded that the two-dose regimen, paired with doxycycline, moxidectin and prednisone, was safe and effective. Its near-comparable efficacy makes the shorter schedule a potentially useful option for shelters under resource pressure.

The mix of shelter and academic partners gives the work a practical focus: the question is whether a treatment schedule can fit the constraints shelters face while still producing strong outcomes. Even so, the report’s conclusion should be read in the context of the trial’s design and participants. The available information identifies the disease classes, sample size and treatment schedules, but it doesn’t establish how broadly the results apply beyond those conditions.

For shelters, the finding may help frame a discussion with veterinary teams about treatment options and capacity. If you’re working in this space, the useful question is not only how many injections a protocol requires, but whether the full course—including medication, restricted activity and follow-up—can be delivered consistently. A shorter schedule could ease one pressure point. The remaining work still counts.

What the results could mean for shelter care

In similar treatment decisions, the operational benefit of a shorter schedule depends on more than the procedure count. A shelter’s ability to keep dogs calm, arrange follow-up and respond to complications also shapes how manageable a course is. The study offers evidence that the two-dose approach can achieve high efficacy in the dogs it followed, alongside the reported survival and complication outcomes. It doesn’t measure adoption effects, shelter throughput or costs, so those potential benefits remain plausible rather than demonstrated here.

That said, the comparison gives shelters a concrete result to consider instead of relying only on assumptions about convenience. The efficacy figures are close, and the difference is still visible. Further experience in other settings could help clarify how well the findings carry over to different shelter routines and patient groups, but the information reported here doesn’t answer that question.

The most grounded takeaway is modest: for dogs with Class 1 or 2 disease in this trial, a two-dose melarsomine course paired with the other listed medications was judged safe and effective, with efficacy near the standard schedule. For shelters under resource pressure, that could widen the practical options available for care. It isn’t a shortcut around follow-up, exercise restriction or clinical judgment.